-
Anlotinib for Intra-Abdominal Desmoplastic Tumor
2026-09-15
This case report describes metastatic intra-abdominal desmoplastic small round cell tumor responding to anlotinib after surgery and adjuvant chemotherapy. The report’s main contribution is case-level evidence that a multi-target tyrosine kinase inhibitor may provide disease control in a rare, aggressive sarcoma, although the findings require validation beyond a single patient.
-
Apicidin: Epigenetic Leverage, Translational Caution
2026-09-15
Apicidin is more than a potent histone deacetylase inhibitor. Its HDAC3 and HDAC6 activity creates a useful bridge between chromatin regulation, cancer biology, angiogenesis, and reproductive toxicology. This thought-leadership analysis translates mechanistic findings into practical assay design, target-validation strategy, and translational risk assessment.
-
Dovitinib (TKI-258, CHIR-258) in Cell Assays
2026-09-14
This scenario-driven guide explains how Dovitinib (TKI-258, CHIR-258), SKU A2168, can improve interpretation of viability, proliferation, and cytotoxicity experiments. It connects target-level potency, solvent handling, protocol design, orthogonal readouts, and practical product-selection criteria for more defensible cancer-cell assays.
-
Diminazene Aceturate: Research Workflows
2026-09-14
Diminazene Aceturate supports two distinct research applications: trypanosome parasite research and mechanistic ACE2 activation studies. This practical guide covers stock preparation, assay design, mitochondrial readouts, controls, and troubleshooting while separating established findings from workflow recommendations.
-
Atrial Natriuretic Peptide: Applied Workflows
2026-09-13
Build reproducible ANP assays for vascular tone, renal sodium handling, and adipose metabolism with practical controls for peptide handling and response timing. This guide also shows how to use the reference study as a design lesson without confusing adiponectin-mediated neuroinflammation with ANP biology.
-
Glycogen Colorimetric Assay Kit II Workflow
2026-09-12
Build a reproducible glycogen assay workflow for liver, muscle, and other biological samples, including matrices where reducing substances complicate oxidase-based measurements. The approach connects high-throughput glycogen quantification with circadian exercise studies, glycogen storage disease research, and practical troubleshooting.
-
Hoechst 33258 for Reliable DNA Staining
2026-09-12
Hoechst 33258, SKU A3466, provides a practical bis-benzimide DNA stain for nuclear visualization in live and fixed cells, microscopy, flow cytometry, and cell-cycle studies. This scenario-based guide explains how to select controls, manage fluorescence, interpret nuclear data, and build a reproducible workflow.
-
Palonosetron for CINV and RINV: Evidence Update
2026-09-11
The 2013 review by Fabi and Malaguti evaluates palonosetron hydrochloride as a long-acting 5-HT3 receptor antagonist for chemotherapy- and radiotherapy-related emesis. Its central contribution is the clinical interpretation of prolonged receptor activity, delayed-phase efficacy, combination antiemetic therapy, and guideline positioning rather than the introduction of a new molecule.
-
Moxidectin: A New Logic for Antifungal Synergy
2026-09-11
Moxidectin is best known as a macrocyclic lactone anthelmintic for parasitic worm control, yet new evidence suggests a mechanistically distinct role in antifungal combination therapy. This article examines how moxidectin-driven ergosterol elevation may potentiate polyenes against Candida albicans, translates the findings into a practical validation framework, and outlines the evidence gaps that must be closed before clinical repositioning.
-
IDO1 Blockade and Tumor-Protective JAK2/STAT3
2026-09-10
The reference study shows that pharmacological IDO1 inhibition can activate antitumor immune cells while simultaneously inducing an IL-6–JAK2–STAT3 survival program in tumor cells. Its single-cell analysis explains how this compensatory response may limit IDO1-directed therapy and supports testing combined IDO1 and JAK2/STAT3 pathway inhibition.
-
PTT and CD47 Blockade in Oral Cancer
2026-09-10
The reference study shows that photothermal therapy (PTT) can complement CD47 blockade in oral squamous cell carcinoma by generating a calreticulin-mediated “eat me” signal and reducing extracellular matrix barriers to macrophage access. Its findings support a mechanistically integrated strategy for improving macrophage-mediated tumor clearance, while remaining preclinical and dependent on validated optical and immunological parameters.
-
Phytol C5616 for Reliable Cell Assays
2026-09-09
A scenario-based guide to using Phytol (SKU C5616) in cell viability, proliferation, and cytotoxicity workflows. It explains RXR biology, solvent controls, dose design, assay interpretation, isomer composition, and documentation needed for reproducible experiments.
-
Dihydroethidium: From Signal to Mechanism
2026-09-09
Dihydroethidium (DHE) is more than a red fluorescent superoxide indicator. This article explains how to design, control, and interpret DHE experiments so oxidative stress signals can be connected to mitochondrial injury, apoptosis, and cardiovascular disease mechanisms.
-
Trifluoperazine 2HCl: Assay Design Across Domains
2026-09-08
Trifluoperazine 2HCl is a dopamine D2 receptor inhibitor that can connect receptor pharmacology with immune-cell assays. This guide develops a practical, evidence-aware framework for interpreting dopaminergic signaling, ROS, autophagy, and host-directed antibacterial experiments without overextending the available evidence.
-
MDL 28170: A Practical Calpain Inhibitor Workflow
2026-09-08
MDL 28170 provides a cell-permeable way to interrogate calpain and cathepsin B in neuroprotection research, apoptosis assays, and ischemia-reperfusion injury models. This workflow connects target engagement to structural, biochemical, and functional readouts while highlighting formulation, timing, and selectivity controls.